Demographic and clinical features of critically ill patients with COVID-19 in Greece: The burden of diabetes and obesity.

AIMS: The aim of the study was to investigate the association between type-2 diabetes mellitus, other underlying diseases and obesity with the outcomes of critically ill Covid-19 patients in Greece. METHODS: In this retrospective observational multi-centre study, data and outcomes of 90 RNA 2109-nCoV confirmed critically ill patients from 8 hospitals throughout Greece, were analysed. All reported information stand through April 13th 2020. RESULTS: The median age of the patients was 65.5 (IQR 56-73), majority were male (80%) and obesity was present in 34.4% of patients most prevalent to younger than 55 years. Hypertension was the prevailing comorbidity (50%), followed by cardiovascular diseases (21.1%) and type-2 diabetes (18.9%). At admission, common symptoms duration had a median of 8 (IQR 5-11) days. A 13.3% of the patients were discharged, 53.4% were still in the ICUs and 28.9% deceased who were hospitalised for fewer days than the survivors [6 (IQR 3-9) vs. 9 (IQR 7-14.5) respectively]. Aging was not a risk factor but diabetes deteriorates the outcomes. Obesity poses a suggestive burden as it was more notable in deceased versus survivors. CONCLUSIONS: Type 2 diabetes and obesity may have contributed to disease severity and mortality in COVID-19 critically ill patients in Greece.

Implementation of EuroSCORE II as an adjunct to APACHE II model and SOFA score, for refining the prognostic accuracy in cardiac surgical patients.

AIM: The aim of this paper was to assess the comparable applicability of European System for Cardiac Operative Risk Evaluation II (EuroSCORE II), Acute Physiology and Chronic Health Evaluation (APACHE II) and Sequential Organ Failure (SOFA) scores, in cardiac surgical population, on the basis of morbidity and mortality. METHODS: EuroSCORE II, APACHE II score and SOFA score derivatives such as TMS (total maximum SOFA), MaxSOFA (single-day maximum total), SOFA 1 (admission SOFA), ΔSOFA (TMS minus SOFA 1), ΔmaxSOFA (MaxSOFA minus SOFA 1) and mean SOFA (daily SOFA to ICU stay), were prospectively calculated for 1058 consecutive patients admitted to postcardiac surgery intensive care unit (ICU). The study endpoints were length of ICU stay (LOS-ICU) and hospital mortality. RESULTS: A disproportionate elevation of the studied algorithms was associated with prolonged LOS-ICU (P<0.001). TMS, MeanSOFA, MaxSOFA and EuroSCORE II provided better discrimination for in-hospital death [area under the receiver operating characteristic curve (AUC) 0.949, 0.929, 0.927 and 0.906, respectively] and LOS-ICU more than 2 days (AUC 0.853, 0.823, 0.819 and 0.806, respectively), compared to other risk models. EuroSCORE II, TMS and MeanSOFA were also identified as independent predictors of prolonged LOS-ICU. CONCLUSION: EuroSCORE II seems to confer noteworthy prognostic value, being almost equivalent to that of TMS, MeanSOFA and MaxSOFA scores, and superior than APACHE II in cardiac surgical population. Thus, EuroSCORE II emerges as an imperative adjunct to ICU-based APACHE II and SOFA algorithms as it enables risk stratification, morbidity and mortality prediction even from preoperative assessment.

PDE5 inhibitors: in vitro and in vivo pharmacological profile.

PDE5 inhibitors have been clearly established as first-line therapy for the treatment of erectile dysfunction (ED). Three PDE5 inhibitors--sildenafil (Viagra), vardenafil (Levitra) and tadalafil (Cialis)--are currently approved by the FDA and the EMEA for use in ED, whereas sildenafil is also marketed under a different proprietary name (Revatio) for the treatment of pulmonary arterial hypertension (PAH). A forth PDE5 inhibitor, udenafil (Zydena), is currently marketed. In the present review the molecular basis and the mechanism of action of PDE5 inhibitors is discussed. In addition experimental and clinical data concerning their effects on different tissues, organs and systems is systematically reviewed and their possible beneficial action in numerous disorders is presented.

Ropivacaine myotoxicity after single intramuscular injection in rats.

BACKGROUND AND OBJECTIVE: We conducted this study in order to evaluate the potential myotoxic effects of ropivacaine after single injection in rats and the time-course of the possible damage. METHODS: One hundred and twenty-eight male Wistar rats were allocated to four different groups. The first three groups received intramuscular injections with ropivacaine 0.75%, ropivacaine 0.5% and normal saline, respectively, into the right tibialis anterior muscle. The fourth group received needle puncture without injection. Eight rats from each group were sacrificed 2, 4, 7 and 30 days after injection. Samples were blindly examined under light microscope for evidence of myotoxicity, scored as 0 = no damage to 3 = myonecrosis and statistically analysed. Samples obtained 7 days after injection were also examined under transmission electron microscope. RESULTS: Ropivacaine 0.75% and ropivacaine 0.5% caused extensive destruction to muscles fibres, compared to saline or needle on days 2, 4 and 7. Statistically significant differences were found in muscle damage by drug injections among all groups except for saline vs. needle groups. Thirty days after injections all sample appearances had returned to normal. CONCLUSIONS: Ropivacaine after single intramuscular injection caused reversible muscle damage in a dose-dependent manner.